DK1480981T3 - 1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater - Google Patents

1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater

Info

Publication number
DK1480981T3
DK1480981T3 DK03709786T DK03709786T DK1480981T3 DK 1480981 T3 DK1480981 T3 DK 1480981T3 DK 03709786 T DK03709786 T DK 03709786T DK 03709786 T DK03709786 T DK 03709786T DK 1480981 T3 DK1480981 T3 DK 1480981T3
Authority
DK
Denmark
Prior art keywords
alkyl
pyrimidin
imidazo
heteroaryl
aryl
Prior art date
Application number
DK03709786T
Other languages
English (en)
Inventor
Alistair Lochead
Philippe Yaiche
Mourad Saady
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK1480981T3 publication Critical patent/DK1480981T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK03709786T 2002-02-28 2003-02-26 1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater DK1480981T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02290487A EP1340759A1 (en) 2002-02-28 2002-02-28 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives

Publications (1)

Publication Number Publication Date
DK1480981T3 true DK1480981T3 (da) 2006-03-20

Family

ID=27675771

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03709786T DK1480981T3 (da) 2002-02-28 2003-02-26 1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater

Country Status (23)

Country Link
US (2) US7429663B2 (da)
EP (2) EP1340759A1 (da)
JP (1) JP4484524B2 (da)
KR (1) KR100935262B1 (da)
CN (1) CN100441581C (da)
AR (1) AR038620A1 (da)
AT (1) ATE309246T1 (da)
AU (1) AU2003214127C1 (da)
BR (1) BR0308106A (da)
CA (1) CA2474875C (da)
DE (1) DE60302220T2 (da)
DK (1) DK1480981T3 (da)
EA (1) EA007459B1 (da)
ES (1) ES2250876T3 (da)
IL (1) IL163288A (da)
MX (1) MXPA04008365A (da)
NO (1) NO329756B1 (da)
NZ (1) NZ534467A (da)
PL (1) PL372664A1 (da)
SI (1) SI1480981T1 (da)
TW (1) TWI305534B (da)
WO (1) WO2003072580A1 (da)
ZA (1) ZA200406154B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2541832C (en) * 2003-10-10 2009-11-24 Pfizer Products Inc. Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2009260526A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted indoles
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DK2448939T3 (da) * 2009-07-02 2017-06-19 Sanofi Sa Derivater af 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-on, fremstilling og farmaceutisk anvendelse heraf
PT3143011T (pt) * 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
CN112574219A (zh) * 2021-01-31 2021-03-30 湖北大学 一种苯并咪唑并嘧啶酮衍生物的合成方法
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184384B1 (en) * 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
CN1246858A (zh) * 1996-12-05 2000-03-08 安姆根有限公司 取代的嘧啶化合物和它们的应用
TWI241298B (en) * 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
EP1184384A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives
EP1295884A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives

Also Published As

Publication number Publication date
AU2003214127B2 (en) 2008-07-03
EP1340759A1 (en) 2003-09-03
CA2474875C (en) 2011-04-12
US7429663B2 (en) 2008-09-30
IL163288A (en) 2009-12-24
KR100935262B1 (ko) 2010-01-06
JP4484524B2 (ja) 2010-06-16
CN1646533A (zh) 2005-07-27
NZ534467A (en) 2006-07-28
CN100441581C (zh) 2008-12-10
EA200400937A1 (ru) 2005-02-24
ES2250876T3 (es) 2006-04-16
EA007459B1 (ru) 2006-10-27
DE60302220T2 (de) 2006-07-27
EP1480981A1 (en) 2004-12-01
US20050119280A1 (en) 2005-06-02
TWI305534B (en) 2009-01-21
CA2474875A1 (en) 2003-09-04
TW200418859A (en) 2004-10-01
US20080318980A1 (en) 2008-12-25
WO2003072580A1 (en) 2003-09-04
AU2003214127C1 (en) 2009-02-05
PL372664A1 (en) 2005-07-25
AR038620A1 (es) 2005-01-19
DE60302220D1 (de) 2005-12-15
SI1480981T1 (sl) 2006-04-30
BR0308106A (pt) 2005-01-04
ATE309246T1 (de) 2005-11-15
NO329756B1 (no) 2010-12-13
EP1480981B1 (en) 2005-11-09
NO20043567L (no) 2004-11-26
AU2003214127A1 (en) 2003-09-09
JP2005519087A (ja) 2005-06-30
KR20040087328A (ko) 2004-10-13
MXPA04008365A (es) 2005-07-26
ZA200406154B (en) 2005-08-02

Similar Documents

Publication Publication Date Title
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
HK1091495A1 (en) Pyrimidin-5(1h)-one derivatives
DE60016615D1 (de) Pyrazolo[4,3-d]pyrimidinderivate
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
TWI346664B (en) Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
IL169335A0 (en) PYRAZOLO[3,4,-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
DK1480981T3 (da) 1-(Alkyl)-, 1-(heteroaryl)alkyl- og 1-[(aryl)alkyl]-7-(pyrimidin-4-yl) imidazo[1,2a]pyrimidin-5(1H)-onderivater
DE69915675D1 (de) Triazolo[4,5-d]pyrimidin-derivate
NO20030033D0 (no) Pyrido[2,3-D]pyrimidin- og pyrimido[4,5-D]pyrimidin- nukleosider
EE05351B1 (et) Prrolo[2,3-d]primidiinhendid
DK1430057T3 (da) Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater
IL163287A (en) HETEROARYL SUBSTITUTED 2 - PYRIDINYL AND 2 - PYRIMIDINYL - 6,7,8,9 - TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
DK1315731T3 (da) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on-derivater
DK1315730T3 (da) 1-(alkyl)-, 1-[(heteroaryl)alkyl]-og 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-onderivater
AU2003211993A1 (en) (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
PL375709A1 (en) Derivatives of [6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
DE50106048D1 (de) Substituierte 3,4-dihydro-pyrimido [1,2-a]pyrimidine und 3,4-dihydropyrazino [1,2-a]pyrimidine
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
DK1325010T3 (da) Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner